MedTrace Logo

Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)

NCT00413829 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-01-14

No results posted yet for this study

Summary

This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg). An evaluation of the short term effects on CNV perfusion of this combined treatment is needed for better understanding of treatment effects.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Intravitreal ranibizumab with photodynamic therapy

Intravitreal injection, photodynamic therapy

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Sebastian Wolf, MD PhD · Klinik und Poliklinik fuer Augenheilkunde, Inselspital

  • Ute Wolf-Schnurrbusch, MD · Klinik und Polklinik fuer Augenheilkunde, Inselspital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-05-31
Completion
2008-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413829 on ClinicalTrials.gov